Head-to-head · free

Dianthus Therapeutics, Inc. vs Doximity, Inc.

DNTH vs DOCS — return on capital, cash generation, margins and balance sheet side by side.

DNTH

0 / 6

measures where DNTH leads

DOCS

6 / 6

measures where DOCS leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureDNTH · FY2025DOCS · FY2026
Revenue$2.0M$644.9M
Net income(162.3M)$196.1M
Revenue growth (yearly, multi-year)-67.3%17.0%
Free cash flow—$326.5M
Free cash flow margin—50.6%
Net cash / (debt)——
ROIC—16.4%
Return on equity-38.4%19.3%
Gross margin—89.1%
Operating margin-8739.3%33.3%
Net debt / EBITDA0.29x-0.96x

Figures are as reported by each company; latest fiscal year shown.

Where Dianthus Therapeutics, Inc.'s cash went (FY2025)

Capital spending
—
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full DNTH profile →

Where Doximity, Inc.'s cash went (FY2026)

Capital spending
$0
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full DOCS profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons